Prescription-based association of P-glycoprotein substrates with Alzheimer's disease risk: A nested case-control study
- 23 June 2025
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (3) , 1063-1073
Abstract
Background: P-glycoprotein (P-gp) is linked to Alzheimer's disease (AD), as P-gp contributes to clearance of amyloid-β (Aβ) from the CNS. Thus, other P-gp substrates (Pgp-S) could affect Aβ clearance, either negatively through competitive inhibition or positively via cooperative transport, impacting risk for AD. Objective: We probed impacts of Pgp-S on AD risk by querying AD rates among individuals prescribed medications that are considered Pgp-S. Methods: A retrospective cohort study was performed using the PharMetrics Plus database (IQVIA), encompassing 70,340 users of prescription drugs identified as Pgp-S and 352,382 Pgp-S non-users. Users and non-users were matched by age, sex, and geographical region. Cox regression models afforded adjustments for covariates and comorbidities. Results: Pgp-S use was generally associated with a significant reduction in the hazard ratio of AD in both crude (HR = 0.89, 95% CI = 0.79–0.99) and matched (HR = 0.87; 95% CI = 0.78–0.98) analyses. AD risk was higher among subsets diagnosed with comorbidities: depression (HR = 4.44; 95% CI, 3.99–4.94), stroke (HR = 1.98, 95% CI = 1.63–2.41), and hypertension (HR = 1.24, 95% CI = 1.13–1.36). In an analysis of individual drugs, digoxin (OR = 0.52, 95% CI, 0.34–0.77), atorvastatin (OR = 0.80, 95% CI, 0.73–0.87), omeprazole (OR = 0.83, 95% CI, 0.73–0.94), and prednisone (OR = 0.64, 95% CI, 0.46–0.86) were associated with significantly decreased odds of incident AD; rivaroxaban (OR = 1.29, 95% CI = 0.97–1.68) and mirabegron (OR = 1.45, 95% CI = 0.86–2.28) trended toward increased risk. Conclusions: The findings suggest an association between Pgp-S use and AD, but limitations of the study design impel additional work to confirm the direction of impact for individual drugs.Keywords
This publication has 52 references indexed in Scilit:
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Comparative in silico prediction of P‐glycoprotein‐mediated transport for 2010–2020 US FDA‐approved drugs using six Web‐toolsBiopharmaceutics & Drug Disposition, 2021
- Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control AnalysisDrug Safety, 2018
- Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) CohortJAMA Neurology, 2017
- About P‐glycoprotein: a new drugable domain is emerging from structural dataWIREs Computational Molecular Science, 2017
- Risk of dementia in elderly patients with the use of proton pump inhibitorsEuropean Archives of Psychiatry and Clinical Neuroscience, 2014
- The performance of different propensity score methods for estimating marginal hazard ratiosStatistics in Medicine, 2012
- Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulationsBiometrical Journal, 2009
- A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin useStatistics in Medicine, 2005
- Alzheimer's disease: A study of epidemiological aspectsAnnals of Neurology, 1984